The intravitreal injectables market will showcase stable growth at a compound annual growth rate (CAGR) of 4.8% during the forecast period from 2018 to 2026. According to the statistics provided by the World Health Organization (WHO), approximately 1.3 billion people throughout the globe are suffering from some form of blindness caused majorly by macular degeneration, diabetic retinopathy, ocular vein occlusions, endophthalmitis, and retinitis. Intravitreal injections are preferred over other treatment options for treating disease-associated visual impairment.
Market Synopsis
Macular degeneration market growth is being driven by rising diabetes prevalence and an aging population.
As per the research cited in the Lancet journal, the global prevalence rate of any age-related macular degeneration is 8.69%, with a higher prevalence rate in the Caucasian population followed by mongoloids. The growing geriatric population, smoking, obesity, genetics, diabetes, and other risk factors all contribute to the occurrence of macular degeneration. Diabetic retinopathy is a secondary disease manifestation occurring in elderly people with a previous history of diabetes. Endophthalmitis is growing at a faster rate owing to the rise in air and water pollution and eye trauma.
Excellent biocompatibility and impressive pharmacodynamic properties drive the anti-VEGF drug market.
Anti-VEGF is dominating the drug class segment for intravitreal injections. Drugs like bevacizumab (Avastin), ranibizumab (Lucentis), and others have been used as first-line therapy in patients with neovascular age-related macular degeneration and ocular vein occlusion since their commercialization in 2006. Its inherent features, such as excellent biocompatibility and impressive pharmacodynamic properties, have led to its increased popularity among ophthalmologists worldwide. Corticosteroids are used as an adjuvant medication to treat inflammation caused by eye infections. Antifungal drugs and antibiotics together are prescribed for eye infections such as endophthalmitis and retinitis.
The rising prevalence of eye disorders, combined with an affordable reimbursement scenario, is driving the growth of the intravitreal injectables market.
In the present situation, North America is responsible for 37% of the market share in the regional segment of the intravitreal injectables market. As per the statistics provided by the Centers for Disease Control and Prevention (CDC), approximately 3.3 million Americans aged 40 years and older are blind or suffer from low vision. The rising prevalence of eye disorders, combined with an affordable reimbursement scenario, is driving market growth in North America. Europe accounts for 26% of the market due to the presence of thriving healthcare infrastructure as well as the headquarters of key players such as Novartis AG, Allergan, Inc., Alimera Sciences, F. Hoffman-La Roche Ltd., and others, which drive the market's growth in Europe. Asia Pacific holds a 20% market share and is keen to capture the regional market in the near future on account of the supportive regulatory environment provided by healthcare agencies and the development of ophthalmic research centers providing optimum eye care.
Periods of History and Forecast
This research report presents the analysis of each segment from 2016 to 2026, considering 2017 as the base year for the research. The compound annual growth rate (CAGR) for each of the respective segments is calculated for the forecast period from 2018 to 2026.
Report Scope by Segments
The market is segmented by indication, drug class, and geography.
Pharmaceutical giants competing to maintain a stronghold in the intravitreal injectables market are Allergan, Inc., Genetech, Inc., Alimera Sciences, Bristol-Myers Squibb Company, Eyetech, Inc., F. Hoffman-La Roche Ltd., Novartis AG, Regeneron Pharmaceuticals, Inc., ThromboGenics, Inc., and Valeant Pharmaceuticals International, Inc.
Key questions are answered in this report.
Which pharmaceutical companies are manufacturing intravitreal injectables for treating eye disorders?
What are the strengths, weaknesses, and opportunities associated with the growth of the intravitreal injectables market?
What is the pathophysiology associated with diseases such as macular degeneration, diabetic retinopathy, and endophthalmitis?
Which treatment regimen is considered for the treatment of macular degeneration?
What is the pharmacodynamic effect of anti-VEGF drugs in treating eye disorders?
What will be the market assessment for intravitreal injectables in the Asia-Pacific regional market?
Frequently Asked Questions:
The market for Intravitreal Injectables Market is expected to reach At XX Mn in 2026.
The Intravitreal Injectables Market is expected to see significant CAGR growth over the coming years, at 4.8%.
The report is forecasted to 2018-2026
The base year of this report is 2017.
Allergan, Inc., Alimera Sciences,Bristol-Myers Squibb Company,Eyetech Inc.,F.Hoffmann-La Roche Ltd. are some of the major players in the global market.
